Literature DB >> 11798075

Expression of prostaglandin D synthase in ovarian cancer.

B Su1, M Guan, R Zhao, Y Lu.   

Abstract

Lipocalin-type prostaglandin D synthase (L-PGDS) has recently been shown to be expressed in human brain tumors and breast tumors. However, L-PGDS expression has not been investigated in ovarian cancer. The objective of this study was to determine whether L-PGDS is expressed in human ovarian cancer. Lipocalin prostaglandin D synthase mRNA was cloned and sequenced by RT-PCR. Using in situ hybridization (ISH) technique, the expression of L-PGDS mRNA in 54 ovarian cancer was investigated. Expression of L-PGDS mRNA was found in tumor cells of all various types of ovarian cancers. Patterns of staining of tumor cells varied among different histological types of ovarian cancer. Significant discrepancy between the intensity of the staining and histological types of ovarian cancer could be established (p<0.01). It is reported for the first time that the expression of mRNA of L-PGDS exists in the ovarian cancer, and is related to the cancer type. This may have significance for the progress of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11798075     DOI: 10.1515/CCLM.2001.190

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  2 in total

1.  Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: A pediatric brain tumor consortium study.

Authors:  Meena U Rajagopal; Yetrib Hathout; Tobey J MacDonald; Mark W Kieran; Sri Gururangan; Susan M Blaney; Peter Phillips; Roger Packer; Heather Gordish-Dressman; Brian R Rood
Journal:  Proteomics       Date:  2011-01-27       Impact factor: 3.984

2.  Molecular identification and expression of differentially regulated genes of the European flounder, Platichthys flesus, submitted to pesticide exposure.

Authors:  J Marchand; A Tanguy; G Charrier; L Quiniou; E Plee-Gauthier; J Laroche
Journal:  Mar Biotechnol (NY)       Date:  2006-03-17       Impact factor: 3.619

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.